Search Results - Manu Thomas Kalathottukaren
- Showing 1 - 4 results of 4
-
1
-
2
Comparison of reversal activity and mechanism of action of UHRA, andexanet, and PER977 on heparin and oral FXa inhibitors by Manu Thomas Kalathottukaren, A. Louise Creagh, Srinivas Abbina, Genmin Lu, Mark J. Karbarz, Anjali Pandey, Pamela B. Conley, Jayachandran N. Kizhakkedathu, Charles A. Haynes
Published 2018Artigo -
3
Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA by Manu Thomas Kalathottukaren, Libin Abraham, Piyushkumar R. Kapopara, Benjamin Lai, Rajesh A. Shenoi, Federico I. Rosell, Edward M. Conway, Edward L.G. Pryzdial, James H. Morrissey, Charles A. Haynes, Jayachandran N. Kizhakkedathu
Published 2016Artigo -
4
Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design by Chanel C. La, Stephanie A. Smith, Sreeparna Vappala, Reheman Adili, Catherine E. Luke, Srinivas Abbina, Haiming D. Luo, Irina Chafeeva, Matthew Drayton, Louise Creagh, Marı́a de Guadalupe Jaraquemada-Peláez, Nicole Rhoads, Manu Thomas Kalathottukaren, Peter K. Henke, Suzana K. Straus, Caigan Du, Edward M. Conway, Michael Holinstat, Charles A. Haynes, James H. Morrissey, Jayachandran N. Kizhakkedathu
Published 2023Artigo
Search Tools:
Related Subjects
Biochemistry
Chemistry
Medicine
Pharmacology
Heparin
Internal medicine
Phosphate
Polyphosphate
Antidote
Thrombosis
Toxicity
Activated clotting time
Anticoagulant
Anticoagulant therapy
Antithrombotic
Bioinformatics
Biology
Drug discovery
Hemostasis
Hemostatic Agent
In vitro
Intensive care medicine
Lung
Mechanism of action
Protamine
Protamine sulfate
Surgery
Virtual screening